Advaite will begin supplying the global market with its COVID-19 rapid response diagnostic testing kits, ADVAITE RAPCOV aims to help efforts to contain the spread of COVID-19 virus infection.

The COVID-19 rapid response test utilizes immunochromatography technique which highlights the presence of anti-COVID-19 IgM and IgG antibodies in their specific bands and verifies the validity of the test with a third control band. Based on the presence or absence of IgM and IgG antibody bands, the COVID-19 rapid response test provides presumptive differentiation between recent and past infections.
 
In light of the World Health Organization’s declaration that coronavirus infection has risen to the level of a pandemic, Advaite intends to distribute COVID-19 diagnostic kits worldwide. The company has filed an application with the U.S. FDA to produce its diagnostic kits under the agency’s Emergency Use Authorization (EUA). Pending FDA EUA, the kits could be available soon in the U.S. for the detection of the COVID-19 virus. Given the diagnostic’s ability to provide results in 15-30 minutes from a drop of fingertip blood, as well as the fact that its use is not limited to the traditional laboratory setting, the Advaite test offers a solution for mass screening.